These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12818730)

  • 1. Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.
    Schieffer B; Drexler H
    Am J Cardiol; 2003 Jun; 91(12A):12H-18H. PubMed ID: 12818730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins: the new aspirin?
    Veillard NR; Mach F
    Cell Mol Life Sci; 2002 Nov; 59(11):1771-86. PubMed ID: 12530513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?
    Heeneman S; Donners MM; Bai L; Daemen MJ
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):345-64. PubMed ID: 17338677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance.
    Meune C; Mourad JJ; Bergmann JF; Spaulding C
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):149-54. PubMed ID: 14608518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia.
    Pitt B
    Am J Cardiol; 1997 Mar; 79(5A):24-8. PubMed ID: 9127618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: potential role of cyclooxygenase-2 inhibition.
    Härtel C; von Puttkamer J; Gallner F; Strunk T; Schultz C
    Scand J Immunol; 2004 Oct; 60(4):412-20. PubMed ID: 15379866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans.
    Cipollone F; Fazia M; Iezzi A; Zucchelli M; Pini B; De Cesare D; Ucchino S; Spigonardo F; Bajocchi G; Bei R; Muraro R; Artese L; Piattelli A; Chiarelli F; Cuccurullo F; Mezzetti A
    Circulation; 2003 Mar; 107(11):1479-85. PubMed ID: 12654603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials.
    Benjamin DJ; Haslam A; Prasad V
    Cancer Med; 2024 Mar; 13(5):e7049. PubMed ID: 38491813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of use of antiplatelet drugs, beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in older patients with coronary artery disease in an academic nursing home.
    Joseph J; Koka M; Aronow WS
    J Am Med Dir Assoc; 2008 Feb; 9(2):124-7. PubMed ID: 18261706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase inhibition in patients with coronary artery disease.
    Frishman WH
    J Am Coll Cardiol; 2004 Feb; 43(4):532-3. PubMed ID: 14975459
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward immunomodulatory and anti-inflammatory properties of statins.
    Arnaud C; Braunersreuther V; Mach F
    Trends Cardiovasc Med; 2005 Aug; 15(6):202-6. PubMed ID: 16182129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation.
    Gryglewski RJ; Chłopicki S; Uracz W; Marcinkiewicz E
    Med Sci Monit; 2001; 7(1):1-16. PubMed ID: 11208485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin sensitivity: implications for patients with coronary artery disease.
    Gollapudi RR; Teirstein PS; Stevenson DD; Simon RA
    JAMA; 2004 Dec; 292(24):3017-23. PubMed ID: 15613671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels.
    Takeda T; Hoshida S; Nishino M; Tanouchi J; Otsu K; Hori M
    Atherosclerosis; 2003 Jul; 169(1):155-8. PubMed ID: 12860262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term adherence with cardiovascular drug regimens.
    Kulkarni SP; Alexander KP; Lytle B; Heiss G; Peterson ED
    Am Heart J; 2006 Jan; 151(1):185-91. PubMed ID: 16368315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular events and COX-2 inhibitors.
    McGeer PL; McGeer EG; Yasojima K
    JAMA; 2001 Dec; 286(22):2810; author reply 2811-2. PubMed ID: 11735747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.